Table 2: Overview of current clinical trials in the field of HNSCC targeting NRs. The NCI protocol ID is given in bold (for further details see:

NRClinical trial / identifierDrugTumor entityPhase

PPARPioglitazone in Preventing Head and Neck Cancer in Patients With Oral Leukoplakia/NCT00099021PioglitazoneHead and Neck Cancer Precancerous/Nonmalignant ConditionPhase II ongoing
Rosiglitazone in Preventing Oral Cancer in Patients With Oral Leukoplakia/NCT00369174RosiglitazoneHead and Neck Cancer Precancerous/Nonmalignant ConditionPhase II completed

RARChemoprevention Study of Oral Cavity Squamous Cell Carcinoma/NCT0020127913-cis Retinoic acidOral Cavity Squamous Cell CarcinomaPhase III completed
Isotretinoin Plus Interferon in Treating Patients With Recurrent Cancer/NCT00002506Isotretinoin (combined with Interferon a)Head and Neck Cancer Esophageal CancerPhase II ongoing
Isotretinoin, Interferon Alpha, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer/NCT00054561Isotretinoin (combined with Interferon a and Vitamin E)Head and Neck CancerPhase III completed

ERCombination Chemotherapy and Tamoxifen in Treating Patients With Solid Tumors/NCT00002608Tamoxifen (combined with Cisplatin and Doxorubicin)Head and Neck CancerPhase II completed